AstraZeneca PLC Leaves Door Ajar To Pfizer Inc., Despite Hurdles

Published: May 15, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

May 14, 2014 -- AstraZeneca's boss said on Wednesday he would engage with Pfizer if the price was right and the risks posed from forcing the British drugmaker's operations into the U.S. company's new three-unit model were addressed.

Chief Executive Pascal Soriot stressed his company had a bright future as a stand-alone firm but acknowledged that shareholders would expect AstraZeneca's board to negotiate if terms were sufficiently attractive in a sweetened offer.

"Every shareholder says at the right level with the right offer you should consider it - that is very clear. But there is nobody who has told us a specific price at which we should engage," he told Reuters in an interview.

Help employers find you! Check out all the jobs and post your resume.

Back to news